← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Psoriasis (ARTISTYK Trial)

Phase 4
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
Screening 3 weeks
Treatment Varies
Follow Up at week 16
Awards & highlights

ARTISTYK Trial Summary

This trial studies how a drug can help improve quality of life for people with psoriasis.

Who is the study for?
This trial is for men and women who have had stable plaque psoriasis for at least 6 months, with moderate-to-severe symptoms. Participants should have a noticeable impact on their quality of life due to psoriasis and be suitable candidates for phototherapy or systemic therapy, with at least 3% body surface area affected.Check my eligibility
What is being tested?
The study is testing the effects of Deucravacitinib on improving the quality of life in people with plaque psoriasis compared to a placebo. It's set in a real-world community setting rather than a hospital.See study design
What are the potential side effects?
While specific side effects are not listed here, Deucravacitinib may cause typical drug-related adverse reactions which can include gastrointestinal issues, headaches, potential skin reactions, or other immune-mediated conditions.

ARTISTYK Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My doctor thinks I should get light or drug treatment.
I have had stable plaque psoriasis for over 6 months without major changes.
I have moderate-to-severe plaque psoriasis.
At least 3% of my skin is affected by my condition.

ARTISTYK Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and at week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants who achieve Dermatology Life Quality Index (DLQI) score 0 or 1
Secondary outcome measures
Change from baseline in whole-body itch Numerical Rating Scale (NRS) score at week 16
Number of participants with a static Physician Global Assessment (s-PGA) score of 0 or 1 who had at least a 2-point reduction from baseline
Number of participants with adverse events (AEs)
+4 more

ARTISTYK Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DeucravacitinibExperimental Treatment1 Intervention
Group II: Placebo then DeucravacitinibPlacebo Group2 Interventions
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,638 Previous Clinical Trials
4,128,340 Total Patients Enrolled
35 Trials studying Psoriasis
19,306 Patients Enrolled for Psoriasis

Media Library

Deucravacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05701995 — Phase 4
Psoriasis Research Study Groups: Deucravacitinib, Placebo then Deucravacitinib
Psoriasis Clinical Trial 2023: Deucravacitinib Highlights & Side Effects. Trial Name: NCT05701995 — Phase 4
Deucravacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05701995 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many sites are currently executing this research trial?

"Arkansas Research Trials, Inc. in North Little Rock and Bakersfield Dermatology Skin cancer Med.Group in Bakersfield are two of the 28 locations currently recruiting patients for this medical trial; Integrative Skin Science and Research in Sacramento is yet another participating site."

Answered by AI

Are there any unoccupied slots in this investigation for participants?

"This particular trial is not accepting any new patients, as indicated by the clinicaltrials.gov listing which was last updated on January 26th 2023. However, there are 163 active studies that people can join at this time."

Answered by AI

Could you discuss the degree of safety associated with Deucravacitinib?

"There is an abundance of evidence suggesting Deucravacitinib's safety, which earns it a 3 rating on our scale. This drug has reached approval status in the Phase 4 trial process."

Answered by AI

Who else is applying?

What site did they apply to?
Riverchase Dermatology
What portion of applicants met pre-screening criteria?
Met criteria
~39 spots leftby Aug 2024